Review Examines Use of Biologics in Atopic, Inflammatory Diseases

January 16th 2021, 12:30pm


A recent review explores the use of biologics in atopic and inflammatory conditions as well as lingering research gaps.

Study Compares Mepolizumab, Benralizumab for Eosinophilic Asthma

January 15th 2021, 5:03pm


Mepolizumab and benralizumab are both potent targets of the interlukin-5 pathway with the ability to significantly reduce eosinophil counts, according to new research published in Allergy, Asthma & Clinical Immunology.

Dr Matthew J. Zirwas on Communicating About AD Treatment Persistence

January 10th 2021, 7:30pm


Patients often ask how long they have to stay on biologic treatment for atopic dermatitis (AD), but there is a risk if therapy is stopped, says Matthew J. Zirwas, MD, a dermatologist in Ohio.

Review Probes Role of Eosinophils in Chronic Rhinosinusitis With, Without Polyps

January 8th 2021, 5:10pm


A review explored the potential role of eosinophils and their mediators in the pathophysiology of chronic rhinosinusitis (CRS) subtypes.

Dr Matthew J. Zirwas: How Launch of New Biologics May Change AD Management

December 31st 2020, 9:45pm


Matthew J. Zirwas, MD, a dermatologist in Ohio, discusses how dermatologists may stratify patients with atopic dermatitis (AD) with the launch of new biologic treatments in 2021.

What a Review Says About Biologics for Allergic Bronchopulmonary Aspergillosis, Asthma, CF

December 27th 2020, 4:15pm


The review of 32 studies revealed that biologic treatment tended to favor patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma rather than those with cystic fibrosis (CF).

Patients With Atopic Dermatitis Report Broad Array of OOP Expenses Related to Disease

December 26th 2020, 10:30pm


In addition to significant morbidity and impaired health-related quality of life, patients with atopic dermatitis have a significant out-of-pocket (OOP) financial burden related to their disease.

Top 5 Most-Read Inflammation Articles of 2020

December 23rd 2020, 1:00pm


This year, the most popular articles and interviews related to the role of inflammation in asthma and other conditions touched on the mechanisms of inflammation, patterns of inhaler use, and the real-world impacts of the monoclonal antibody dupilumab.

Subgroup Analysis Confirms Safety, Efficacy of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps

December 19th 2020, 2:30pm


The analysis reviewed the safety and efficacy among patients in Japan to confirm the findings of the overall study population.

Dr David Pariser Outlines Unmet Needs in Treatment Options for Atopic Dermatitis

December 18th 2020, 3:45pm


The treatment landscape for atopic dermatitis is beginning to change from the use of topical therapies to biologics and more, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.